Panel: Antibodies for Cancer Therapy: Emerging Targets, Smarter Payloads & Clinical Momentum

Session details:

As antibody-based therapies continue to dominate the oncology pipeline, innovation in target selection, linker-payload design, and clinical development strategy is driving a new wave of therapeutic breakthroughs. This panel will explore how next-gen antibodies and ADCs are expanding into new tumor types, improving therapeutic index, and redefining success in solid tumors and hematologic cancers alike.

• Novel and next-generation targets in oncology and immune modulation
• Design considerations for next-gen ADCs: linkers, payloads, and conjugation tech
• Translational insights: biomarker strategies, patient selection, and resistance mechanisms
• Clinical and regulatory lessons from recent ADC approvals and pipeline milestones